AI assistant
VOLITIONRX LTD — Director's Dealing 2021
Nov 5, 2021
34395_dirs_2021-11-05_5602e809-713d-459e-9ef2-fb62572aadbe.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2021-11-03-05:00
Reporting Person: Innes Guy Archibald (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-03-05:00 | Stock Option (Right to Buy) | $4.00 | D | 30000 | Disposed | 2022-04-15-05:00 | Common Stock (30000) | Direct |
| 2021-11-03-05:00 | Stock Option (Right to Buy) | $4.00 | A | 30000 | Acquired | 2026-04-15-05:00 | Common Stock (30000) | Direct |
| 2021-11-03-05:00 | Stock Option (Right to Buy) | $5.00 | D | 20000 | Disposed | 2023-03-30-05:00 | Common Stock (20000) | Direct |
| 2021-11-03-05:00 | Stock Option (Right to Buy) | $5.00 | A | 20000 | Acquired | 2027-03-30-05:00 | Common Stock (20000) | Direct |
| 2021-11-03-05:00 | Stock Option (Right to Buy) | $4.00 | D | 20000 | Disposed | 2024-01-23-05:00 | Common Stock (20000) | Direct |
| 2021-11-03-05:00 | Stock Option (Right to Buy) | $4.00 | A | 20000 | Acquired | 2028-01-23-05:00 | Common Stock (20000) | Direct |
Footnotes
F1: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).
F2: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on March 30, 2017, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on March 30, 2027 (ten years from the original date of grant).
F3: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).